ALKemist Bio
Reprogramming Immunity for ALK+ Cancer Care
- Website
- alkemistbio.com
- Total Funding
- $8.0M
- Last Round
- $8.0M Venture RoundDec 2023
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
ALKemist Bio develops next-generation cell therapies for cancers driven by the ALK oncogene. Its approach engineers a patient's own T cells outside the body with synthetic CAR and TCR receptors designed to recognize ALK proteins. The company is pursuing applications in ALK-positive lymphoma, neuroblastoma, and non-small-cell lung cancer, with the aim of restoring durable immune surveillance after tumor resistance to standard treatments.
Summary
ALKemist Bio is a Biotech company. It has raised $8.0M in total across 1 round, most recently a $8.0M Venture Round in Dec 2023. Investors include Claris Ventures and LIFTT EuroInvest.
Tech & App Stack
1 technology or app tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Dec 2023
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/alkemist-bio"><img src="https://indexed.vc/api/badge/company/alkemist-bio" alt="ALKemist Bio on Indexed.vc" width="260" height="76" /></a>